AI for Pharma & Healthcare 2025

Oxford University’s Covid-19 vaccine shows promise in animal study

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Philips, Masimo Extend Partnership to Sensor...

Philips and Masimo have gone on to renew their...

Renovo from China Raises $67M Series...

Ronovo Surgical from China has gone on to close...

NHS Boards to Explore Joint Working...

In a recent update, two NHS boards to explore...

NHS Performance Standards Tested as Patients...

The NHS in England has remained under relentless pressure...

The University of Oxford in the UK has reported positive findings of its Covid-19 vaccine candidate in a small preclinical study involving six monkeys.

This preliminary data of the vaccine, currently in human trials, has been published on the preprint website bioRxiv, noted Reuters.

According to the publication, some monkeys administered with a single shot of the vaccine generated antibodies against the virus within 14 days while all monkeys developed antibodies within 28 days, prior to being exposed to high virus doses.

Following exposure to the coronavirus, the vaccine candidate was prevented damage to the lungs and blocked the virus from replication. However, the virus was found to be actively replicating in the nose.

London School of Hygiene & Tropical Medicine pharmacoepidemiology professor Stephen Evans said that the animal data was ‘good news’. Evans was quoted as saying: “It is one of the hurdles to be passed by the Oxford vaccine and it has cleared it well.”

The professor also noted that no evidence of immune-enhanced disease, where a vaccine makes the disease worse, was reassuring.

Evans added: “This was a definite theoretical concern for a vaccine against SARS-CoV-2 and finding no evidence for it in this study is very encouraging.”

Last month, the University of Oxford signed an agreement with AstraZeneca to develop and distribute its Covid-19 vaccine candidate, a recombinant adenovirus vaccine in development by Jenner Institute and Oxford Vaccine Group at the university.

Results from the human trial are expected next month, with plans to start late-stage trials by the middle of this year. As part of the deal, AstraZeneca will carry out the development and global manufacturing and distribution of the vaccine.

Latest stories

Related stories

Philips, Masimo Extend Partnership to Sensor Technologies

Philips and Masimo have gone on to renew their...

Renovo from China Raises $67M Series D Funding by JJDC

Ronovo Surgical from China has gone on to close...

NHS Boards to Explore Joint Working in Sussex and Surrey

In a recent update, two NHS boards to explore...

NHS Performance Standards Tested as Patients Volume Grows

The NHS in England has remained under relentless pressure...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »